

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

WM3918

RRID:CVCL_C279

Type: Cell Line

Proper Citation

RRID:CVCL_C279

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_C279

Proper Citation: RRID:CVCL_C279

Description: Cell line WM3918 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Melanoma

Defining Citation: [PMID:24576830](#)

Comments: Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in Cellosaurus and May 2018. The major changes were: D18S51., Part of: Wistar Institute melanoma cell line collection.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: WM3918

Synonyms: WM-3918, WM 3918

Cross References: cancercellines:CVCL_C279, GEO:GSM952608, Progenetix:CVCL_C279, Rockland:WM3918-01-0001, Wikidata:Q54994303

ID: CVCL_C279

Record Creation Time: 20220427T221722+0000

Record Last Update: 20260830T000326+0000

Ratings and Alerts

No rating or validation information has been found for WM3918.

No alerts have been found for WM3918.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sung HM, et al. (2026) Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity. *Molecular oncology*, 20(5), 1161.

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF β complex for genomic stability. *Cell reports*, 44(11), 116495.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. *Cancer research*, 85(9), 1611.

Gupta PK, et al. (2024) Metabolic Imaging Biomarkers of Response to Signaling Inhibition Therapy in Melanoma. *Cancers*, 16(2).

Nguyen TT, et al. (2021) Mutations in the IFN γ -JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(12), 3432.